PSCH250117C47000
- 0.00
- 0.000.00%
Invesco S&P Smallcap Health Care Etf Newsroom
(GKOS) - Analyzing Glaukos's Short Interest
Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $114 Price Target
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Price Over Earnings Overview: Merit Medical Systems
Hims & Hers Health Are Falling Today: What's Going On?
FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
FDA Issued A New Decision Determining The Tirzepatide Injection Shortage Is Resolved
10 Health Care Stocks With Whale Alerts In Today's Session
Hims & Hers Health Options Trading: A Deep Dive Into Market Sentiment
Hims & Hers Health Analyst Ratings
Merit Medical Announces Resignation Of President, Joseph Wright, Effective January 3, 2025; Board Of Directors Has Re-Appointed Fred P. Lampropoulos As Merit's President
Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Wall Street is hot on quantum computing stocks, but Google's quantum chip does not actually possess computing power.
Google unveiled its new "quantum chip" Willow this Tuesday, causing its parent company Alphabet and related Stocks to surge significantly this week. However, Analysts indicate that quantum computing is still a long way from any commercial use and advise investors not to get overly excited due to the recent rise.
Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes
Josh Brown Unveils The 'Degen Dow,' A Basket Of 30 Retail Darlings Spanning All 'Major Degen Food Groups'
Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Hims & Hers Health Unusual Options Activity
Merit Medical Systems Analyst Ratings